BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 33995393)

  • 1. Anti-HIV-1 ADCC and HIV-1 Env Can Be Partners in Reducing Latent HIV Reservoir.
    Suryawanshi P; Bagul R; Shete A; Thakar M
    Front Immunol; 2021; 12():663919. PubMed ID: 33995393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells.
    Lee WS; Richard J; Lichtfuss M; Smith AB; Park J; Courter JR; Melillo BN; Sodroski JG; Kaufmann DE; Finzi A; Parsons MS; Kent SJ
    J Virol; 2016 Feb; 90(4):2021-30. PubMed ID: 26656700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-gp140-Specific Antibodies Generated From Indian Long-Term Non-Progressors Mediate Potent ADCC Activity and Effectively Lyse Reactivated HIV Reservoir.
    Dhande JR; Bagul RD; Thakar MR
    Front Immunol; 2022; 13():844610. PubMed ID: 35309295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Combination Antiretroviral Therapy on HIV-1-specific Antibody-Dependent Cellular Cytotoxicity Responses in Subtype B- and Subtype C-Infected Cohorts.
    Madhavi V; Kulkarni A; Shete A; Lee WS; Mclean MR; Kristensen AB; Ghate M; Wines BD; Hogarth PM; Parsons MS; Kelleher A; Cooper DA; Amin J; Emery S; Thakar M; Kent SJ;
    J Acquir Immune Defic Syndr; 2017 Jul; 75(3):345-353. PubMed ID: 28346319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.
    Lee WS; Kristensen AB; Rasmussen TA; Tolstrup M; Østergaard L; Søgaard OS; Wines BD; Hogarth PM; Reynaldi A; Davenport MP; Emery S; Amin J; Cooper DA; Kan VL; Fox J; Gruell H; Parsons MS; Kent SJ
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1.
    Bertagnolli LN; Varriale J; Sweet S; Brockhurst J; Simonetti FR; White J; Beg S; Lynn K; Mounzer K; Frank I; Tebas P; Bar KJ; Montaner LJ; Siliciano RF; Siliciano JD
    Proc Natl Acad Sci U S A; 2020 Dec; 117(50):32066-32077. PubMed ID: 33239444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity.
    Veillette M; Désormeaux A; Medjahed H; Gharsallah NE; Coutu M; Baalwa J; Guan Y; Lewis G; Ferrari G; Hahn BH; Haynes BF; Robinson JE; Kaufmann DE; Bonsignori M; Sodroski J; Finzi A
    J Virol; 2014 Mar; 88(5):2633-44. PubMed ID: 24352444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. eCD4-Ig promotes ADCC activity of sera from HIV-1-infected patients.
    Davis-Gardner ME; Gardner MR; Alfant B; Farzan M
    PLoS Pathog; 2017 Dec; 13(12):e1006786. PubMed ID: 29253851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses.
    Prévost J; Richard J; Medjahed H; Alexander A; Jones J; Kappes JC; Ochsenbauer C; Finzi A
    J Virol; 2018 Jul; 92(13):. PubMed ID: 29669829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A defucosylated bispecific multivalent molecule exhibits broad HIV-1-neutralizing activity and enhanced antibody-dependent cellular cytotoxicity against reactivated HIV-1 latently infected cells.
    Kong D; Wang Y; Ji P; Li W; Ying T; Huang J; Wang C; Wu Y; Wang Y; Chen W; Hao Y; Hong K; Shao Y; Dimitrov DS; Jiang S; Ma L
    AIDS; 2018 Aug; 32(13):1749-1761. PubMed ID: 29762173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.
    Tuyishime M; Garrido C; Jha S; Moeser M; Mielke D; LaBranche C; Montefiori D; Haynes BF; Joseph S; Margolis DM; Ferrari G
    J Clin Invest; 2020 Oct; 130(10):5157-5170. PubMed ID: 32584790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4- and Time-Dependent Susceptibility of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity.
    Lee WS; Prévost J; Richard J; van der Sluis RM; Lewin SR; Pazgier M; Finzi A; Parsons MS; Kent SJ
    J Virol; 2019 May; 93(10):. PubMed ID: 30842324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations.
    Grau-Expósito J; Luque-Ballesteros L; Navarro J; Curran A; Burgos J; Ribera E; Torrella A; Planas B; Badía R; Martin-Castillo M; Fernández-Sojo J; Genescà M; Falcó V; Buzon MJ
    PLoS Pathog; 2019 Aug; 15(8):e1007991. PubMed ID: 31425551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
    Cillo AR; Sobolewski MD; Bosch RJ; Fyne E; Piatak M; Coffin JM; Mellors JW
    Proc Natl Acad Sci U S A; 2014 May; 111(19):7078-83. PubMed ID: 24706775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.
    Sung JA; Pickeral J; Liu L; Stanfield-Oakley SA; Lam CY; Garrido C; Pollara J; LaBranche C; Bonsignori M; Moody MA; Yang Y; Parks R; Archin N; Allard B; Kirchherr J; Kuruc JD; Gay CL; Cohen MS; Ochsenbauer C; Soderberg K; Liao HX; Montefiori D; Moore P; Johnson S; Koenig S; Haynes BF; Nordstrom JL; Margolis DM; Ferrari G
    J Clin Invest; 2015 Nov; 125(11):4077-90. PubMed ID: 26413868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent
    Bardhi A; Wu Y; Chen W; Li W; Zhu Z; Zheng JH; Wong H; Jeng E; Jones J; Ochsenbauer C; Kappes JC; Dimitrov DS; Ying T; Goldstein H
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28794022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nef Proteins from HIV-1 Elite Controllers Are Inefficient at Preventing Antibody-Dependent Cellular Cytotoxicity.
    Alsahafi N; Ding S; Richard J; Markle T; Brassard N; Walker B; Lewis GK; Kaufmann DE; Brockman MA; Finzi A
    J Virol; 2015 Dec; 90(6):2993-3002. PubMed ID: 26719277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins.
    Richard J; Pacheco B; Gohain N; Veillette M; Ding S; Alsahafi N; Tolbert WD; Prévost J; Chapleau JP; Coutu M; Jia M; Brassard N; Park J; Courter JR; Melillo B; Martin L; Tremblay C; Hahn BH; Kaufmann DE; Wu X; Smith AB; Sodroski J; Pazgier M; Finzi A
    EBioMedicine; 2016 Oct; 12():208-218. PubMed ID: 27633463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.